Deerfield Management Company, L.P. (Series C) Biogen Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Biogen Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,504 shares of BIIB stock, worth $513,230. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,504
Previous 931
276.37%
Holding current value
$513,230
Previous $215,000
215.81%
% of portfolio
0.01%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding BIIB
# of Institutions
1,037Shares Held
126MCall Options Held
1.13MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.44 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.39 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.13 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.08 Billion0.06% of portfolio
-
Wellington Management Group LLP Boston, MA5.13MShares$752 Million0.18% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $21.1B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...